Gastric cancer is one of the main causes of cancer-related deaths around the world. The prevalence of early gastric cancer (EGC) among all gastric cancers of 45%-51% in Japan, but only 7%-28% in Western countries. The prevalence of EGC is growing partly because of better diagnostics and screening programmes. Possible treatment options for EGC treatment are expanded by the introduction of endoscopic mucosal resection and endoscopic submucosal dissection Therefore, detailed knowledge about nodal metastatic risk is warranted. We performed a systematic review of the literature concerning studies investigating the role of sentinel lymph node biopsy in EGCr and whether there is enough prove to introduce SLN as a part of treatment for EGC in the Netherlands. Several detection substances (dye or radiocolloid) and injection methods (submucosal or subserosal) are investigated. An overall sensitivity percentage of 85.4% was found. In comparison, high and clinically sufficient percentages were observed for specificity (98.2%), negative predictive value (90.7%) and accuracy (94%). Subgroup analyses showed that the combination of dye and radiocolloid detection substances is the best method for sentinel lymph node detection in early gastric cancer. However, the precise method of sentinel lymph node biopsy in EGC has to be determined further. Large, randomized series should be initiated in Europe to address this issue.
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Introduction
Early gastric cancer (EGC) is defined as tumor invasion confined to the mucosa or submucosa, irrespective of nodal metastases, i.e. T1N0-2 (see Table 1 ). This definition reflects an appreciation that EGC represents a subset of gastric cancers that has a favorable prognosis compared to invasive gastric cancers that extend beyond the submucosa (T2-4). Gastric cancer is one of the most common causes of cancer mortality worldwide. The incidence of gastric cancer and the percentage of gastric cancerrelated deaths are unevenly distributed throughout the world. The disease is most common in the Eastern World with the prevalence of EGC among all gastric cancers 45%-51% in Japan, but only 7%-28% in western countries.(1) Differences in treatment strategies for EGC between Japan and western countries are maintained.(1) Most screening programmes for gastric cancer have been developed in Asian countries. (2) In the Netherlands the primary curative therapy of all stages of gastric cancer consists of the complete resection of the tumor and prophylactic lymph node dissection. The extent of lymph node dissection is still much debated.(3) However, the need for a prophylactic lymph node dissection in EGC is probably negligible with respect to locoregional recurrence and overall survival, because of the very low risk of finding positive lymph nodes (see Table 1 ). (4, 5) It is estimated that 80 to 97% of the patients with EGC do not benefit from a lymphadenectomy, but are harmed by the coinciding morbidity. Non-invasive and endoscopic techniques as computed tomography (CT), magnetic resonance imaging (MRI) and endoscopic ultrasonography (EUS) are limited by their low sensitivity rates in predicting lymph node metastases in gastric cancer. For this problem sentinel lymph node biopsy could be helpful. (6) Investigators from the East and West are stimulated to conduct multiple studies investigating the role of sentinel lymph node (SLN) biopsy in EGC in the past decade. The surgical treatment of early gastric cancer relates to the extend of lymphadenectomy. Therefore detailed knowledge about the nodal metastatic risk is warranted. In this systematic review we investigate whether there is enough prove to introduce SLN as a treatment for EGC in the Netherlands. 
Methods
Systematic search
Relevant studies were identified through a search of the electronic database PubMed. The following search terms were used: "gastric cancer", "gastric carcinoma", "early gastric cancer", "sentinel lymph node", "sentinel node". Inclusion criteria were: study objective to investigate the role of SLN biopsy in gastric cancer, article in the English language and inclusion of at least 10 patients in the study.
Twenty-one studies fulfilled the inclusion criteria. Subsequently, reference lists of the selected studies were crosschecked. The selection and analysis of studies has been performed independently by three investigators (DJL, HWS, RLAL, AED). Studies available for analysis (ref (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) ) were subjected to a quality control using the QUADAS tool. (27) Quality was considered to be good for two studies, moderate for 12 studies and poor for four studies. The selection and analysis of the studies has been performed independently by three investigators (DJL, HWS, AED).
Statistics
The following definitions were used: 
Results
An overview of the results from the studies included in the analysis is presented in Table 2 . A total of 1314 patients were included in the 21 reviewed studies, with a mean number of 63 patients per study (range 13 -211; median 53). Tumor depth varied between T1 and T3 between the studies. All studies excluded patients with metastatic disease. Largely, the SLN detection methods used in these studies can be separated on the basis of detection substance employed into two groups, i.e. radiocolloid or dye. Four of the 21 studies investigated multiple modalities for SLN biopsy. (11, 20, 22, 25, 26) In 16 of the 21 studies a detection dye (indocyanine green, isosulfan blue or patent blue) was used (7, (9) (10) (11) (12) (13) (14) (15) (18) (19) (20) (22) (23) (24) 26) , while a radiocolloid ( 99m Tc tin colloid, 99m Tc sulphur colloid or 99m Tc colloidal rhenium sulphide) was used in nine. (8, 11, (15) (16) (17) 21, 22, 25, 26) Of these 21 studies one compared, but did not combine both methods. (22) In 3 other studies the combination of a dye and radiocolloid was used to maximize SLN detection. (11, 15, 26) The method of application (pre-/peroperative and submucosal/serosal) is depending on the substance employed. All studies using a radiocolloid injected the detection substance peritumorally in the submucosal layer of the stomach via endoscopic route one day preoperatively. In nine out of 17 an endoscope was used in to inject the dye in the submucosal layer (10) (11) (12) 15, 18, 20, 22, 23, 26) , while 8/17 injected the detection substance peritumorally in the subserosal layer during laparotomy. (7, 9, 13, 14, 19, 23, 24) In one study the detection effect of indocyanine green was enhanced by using infrared ray electronic endoscopy (IREE). (18) Another study using dye detection investigated the difference between the submucosal and subserosal techniques (23) , three others used the submucosal dye application in combination with a radiocolloid. (11, 15, 26) The SLN detection rates varied from 66.7% to 100% (mean 94.7%; median 96.6) between the studies. The low SLN detection rate of 66.7% was observed in the study investigating the role of the size of radiocolloid-particles related to detection success. A detection rate of 66.7% was found with a particle size of 500 nm, while with the other investigated particle sizes of 100 and 50 nm detection rates of 100% were observed. The three dye and radiocolloid combination studies showed detection rates of respectively 100%, 100% and 97%. With all detection methods combined, a mean of 3.5 SLNs per patient was observed (range 1.6 -10.5; median 3). The highest number of SLNs per patient was found with the combination of indocyanine green and IREE; here, the detection rate was 98.8%. SLN positivity (SLN+) varied significantly between studies with a range of 5.2% to 73.4% (mean 28.1%; median 21.4%). No association could be observed between tumour depth and SLN+ as result of the given data. Subgroup analyses according to detection method (see Table 4 ) showed better discriminative power for the radiocolloid detection method then dye methods, irrespective of the application method of the dye. However, a tendency towards the best discriminative power was seen for the combination of dye and radiocolloid. 
Discussion
In this systematic review of the current literature not enough prove was found to introduce SLNB in the treatment protocol for EGC in the Netherlands. The overall sensitivity of <90% is just too low to justify immediate introduction of the SLN biopsy procedure in EGC in analogy of the requested sensitivity percentage of > 95% for SLN biopsy as in other solid organ malignancies. For a proper implementation of the SLN biopsy procedure in early gastric cancer several problems need to be solved. First, the amount of false-negative SLN biopsy results should be limited to increase the sensitivity of the procedure. A sensitivity of at least 90-95% should be guaranteed for safe introduction of the procedure in patient care. The lack of expertise is part of the explanation for the current low sensitivity. Several investigators report a significant increase in the sensitivity of SLN biopsy with growing experience with the procedure,(20,24) but it is not known exactly how many patients are needed to complete the learning curve. (24) Although some investigators claim that they were able to optimize their technique with a learning curve of less than ten cases, (20) it seems reasonable to assume that the plateau-phase in the learning curve is reached when detection and accuracy rates are around 95%. Secondly the literature about EGC and SLN procedures is mainly coming from the Asian countries. Because the incidence of gastric cancer is higher in these countries and because the tumour types seem to differ, it may be hazardous to extrapolate the results from these studies to patients in Western countries. (29, 30) One of the differences is the frequency of the locations of the gastric tumors related to the differences in risk factors. The most important risk factor for gastric cancer is an infection by Helicobacter pylori bacteria. This infection is primarily related to distal gastric cancer, (29) which is where most of the tumours of patients from the Eastern world are primarily located. This in contrast to the countries in the in the Western world where most of the gastric cancers are located in the cardia. This difference, among others, can be of importance for the ability of the SNL procedure to detect positive lymph nodes.
In the papers included in our review no clear distinction is made between early gastric cancer(T1) and locally advanced gastric cancer (T2-4). Therefore, not all results are comparable. However, we can postulate that the SLN biopsy procedure could be relevant for clinical practice in EGC to limit the extent of surgery. Lymph node metastases are present in 84% of all patients with gastric cancer (ref 30, table   1 ). Based on current knowledge prophylactic lymphadenectomy could be omitted in patients with a T1 tumor and SLN biopsy negative for metastasis. In these patients, the finding of a positive SLN biopsy should be followed by a lymphadenectomy as part of standard therapy. Lymphadenectomy should also be applied as a standard procedure for patients with T2 ,T3 and T4 tumours, because for patients with these stages of gastric cancer the risk of lymph node metastasis is well above 50%(table 1) and using SLN biopsy will not be of any benefit for them.
Considering all the above, the combination of dye and radiocolloid for lymph node detection is the best 
